Evaluation of the effect of L-Carnitine on patients with moderate to severe condition of Covid-19 ‎admitted to critical care unit

Evaluation of the effect of L-Carnitine on patients with moderate to severe condition of Covid-19 ‎admitted to critical care unit

The study will be double blind and clinical trial.64 patients will be randomly divide into 2 groups. The groups are parallel. The trial phase is 3.

Patients with Covid-19 with moderate disease severity (with Apache score above 25) severely hospitalized in intensive care units of Amir Al-Momenin Hospital in Arak are divided into 2 groups by simple randomization with envelopes. The study is double-blind in which outcome evaluator and data analyst and participant are kept blind.

Inclusion criteria:Suffering Covid-19 without intubation, apache less than 25, 28 to 75 years, absence of acute asthma, absence of acute pulmonary hemorrhage, absence of lung tumor, absence of untreated pneumothorax, do not take anticoagulants (coumadin group such as warfarin), no history of kidney or liver disease, no diabetes (because of the risk of hypoglycemia), no history of seizures Exclusion criteria:Death ,patient dissatisfaction with attending the study for any reason

Intervention group: In addition to routine treatment, patients will receive 1 gram of L-carnitine supplement per day (Karen 1000 mg L-carnitine tablets) for 7 days. Control group: Routine treatment of patients receiving Covid-19 based on protocol with placebo.

Intravenous blood gas samples, disease severity, length of hospital stay, mortality

Simple individual randomization with random allocation with envelopes in 3 groups A and B and C. In this method, we selected a number of cards or letters as an intervention group and the same ‎number of cards for the control group, then the cards were merged. One card was taken out and its ‎allocation was registered and the card was returned to the other cards after leaving. Then the cards ‎are merged again and we remove another card. This process continues to reach a random sequence ‎according to sample size.

In terms of patient blindness, the complementary intern does not know the groupings, and general anesthesia and drug injections are performed by an anesthesiologist. Outcome assessor and data analyzer and participant are blind (double blind). Outcome assessor and data analyzer and participant don't aware from grouping. The intern is unaware of the drugs prescribed in each group and the anesthesiologist prepares the drugs and provides them to the intern. Also, the patients do not know about their group.